Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.
Description
Recursion is a leading TechBio innovator using artificial intelligence to radically improve how new medicines are discovered and developed. The company was founded on the idea that images of cells could be used to train AI systems to understand disease biology at scale. By combining data, machine learning models, and powerful computing, Recursion works to overcome the inefficiencies of traditional drug discovery. Its Recursion OS platform connects massive proprietary biological datasets with automated experimentation and AI-driven insights. This approach has produced a growing pipeline of potential therapies for oncology and rare diseases with high unmet medical needs. Recursion has demonstrated significant gains in speed, efficiency, and cost reduction compared to conventional pharmaceutical methods. Strategic partnerships with pharmaceutical companies and technology leaders expand the reach of its platform. The company also collaborates with NVIDIA to power its discovery efforts using BioHive-2, one of the most advanced supercomputers in biopharma. Together, these capabilities position Recursion as a leader in AI-driven drug discovery. Its ultimate goal is to deliver better medicines to patients through precision design and data-driven science.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Atomwise
Founded
2012
Country
United States
Website
www.atomwise.com
Vendor Details
Company Name
Recursion
Country
United States
Website
www.recursion.com